Lupin's Mandideep Unit II facility in Madhya Pradesh receives EIR from USFDA
Pharma major Lupin on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Mandideep Unit II facility in Madhya Pradesh
New Delhi: Pharma major Lupin on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Mandideep Unit II facility in Madhya Pradesh.
The inspection at the facility was carried out by the US Food and Drug Administration between 26 November, 2018, and 4 December, 2018.
In a filing to BSE, the company said Lupin has received the EIR after closure of the USFDA inspection of its Mandideep Unit II facility, classifying the inspection as "Voluntary Action Indicated."
"We are pleased to have received the EIR for our Mandideep Unit II facility, our important cardiovascular active pharmaceutical ingredients (API) manufacturing facility," Lupin Managing Director Nilesh Gupta said.
The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the US, India, South Africa and across Asia Pacific, Latin America, Europe and Middle-East regions.
The shares of Lupin Ltd were trading at Rs 851.70 a piece on BSE in morning trade, up 3.12 percent from the previous close.
The drug Baricitinib will be used in combination with Remdesivir for the treatment of patients requiring supplemental oxygen, invasive mechanical ventilation, Eli Lilly and Company said in a statement
The new dates of exams and downloading of admit cards will be decided after 15 June on assessment of the situation.
The role of the Sackler family and their company, Purdue Pharma, in developing the prescription painkiller OxyContin is familiar territory. Gibney’s film digs into the aftermath, including the push to get doctors to overprescribe the medication and the company’s use of former government regulators to cripple serious oversight.